Phase III trial of LX 4211 in patients with type 2 diabetes mellitus.

Trial Profile

Phase III trial of LX 4211 in patients with type 2 diabetes mellitus.

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs Sotagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 09 Sep 2016 According to a Lexicon media release, Sanofi is expected to commence this study by the end of the 2016.
    • 02 Mar 2016 Planned initiation date changed from 1 Jan 2016 to 1 Nov 2016, as reported by Lexicon media release.
    • 09 Feb 2016 Planned initiation date changed to 1 Jan 2016, according to a Sanofi media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top